IDXG vs. AVGR, INBS, TMDIF, VVOS, VAPO, VERO, STSS, AFIB, OSA, and GMVDF
Should you be buying Interpace Biosciences stock or one of its competitors? The main competitors of Interpace Biosciences include Avinger (AVGR), Intelligent Bio Solutions (INBS), Titan Medical (TMDIF), Vivos Therapeutics (VVOS), Vapotherm (VAPO), Venus Concept (VERO), Sharps Technology (STSS), Acutus Medical (AFIB), ProSomnus (OSA), and G Medical Innovations (GMVDF). These companies are all part of the "surgical & medical instruments" industry.
Interpace Biosciences (NASDAQ:IDXG) and Avinger (NASDAQ:AVGR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, community ranking, risk, dividends, earnings and valuation.
Interpace Biosciences has higher revenue and earnings than Avinger. Interpace Biosciences is trading at a lower price-to-earnings ratio than Avinger, indicating that it is currently the more affordable of the two stocks.
Interpace Biosciences has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500. Comparatively, Avinger has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500.
Avinger has a consensus target price of $5.00, indicating a potential upside of 28.53%. Given Avinger's higher probable upside, analysts clearly believe Avinger is more favorable than Interpace Biosciences.
5.7% of Interpace Biosciences shares are owned by institutional investors. Comparatively, 18.3% of Avinger shares are owned by institutional investors. 6.5% of Interpace Biosciences shares are owned by insiders. Comparatively, 11.4% of Avinger shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Avinger received 74 more outperform votes than Interpace Biosciences when rated by MarketBeat users. However, 72.83% of users gave Interpace Biosciences an outperform vote while only 59.73% of users gave Avinger an outperform vote.
Interpace Biosciences has a net margin of 1.99% compared to Avinger's net margin of -239.41%. Avinger's return on equity of 0.00% beat Interpace Biosciences' return on equity.
In the previous week, Interpace Biosciences' average media sentiment score of 0.00 equaled Avinger'saverage media sentiment score.
Summary
Avinger beats Interpace Biosciences on 9 of the 15 factors compared between the two stocks.
Get Interpace Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for IDXG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IDXG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Interpace Biosciences Competitors List
Related Companies and Tools
